Dr. Huifeng Hao , Peking University Cancer Hospital , China
Dr. Huifeng Hao is an Assistant Investigator at Peking University Cancer Hospital, specializing in the integration of Chinese and Western medicine. He holds a Ph.D. from Peking University Health Science Center, where he explored Chinese-Western medical integration. His research journey began with a Bachelor’s in Clinical Medicine from Hebei Medical University. Dr. Hao has accumulated valuable postdoctoral experience at Peking Union Medical College (PUMC) in Vascular Pharmacology. His work has greatly contributed to the understanding of cancer progression, focusing on the interactions between cancer cells and vascular endothelial cells and the therapeutic effects of Traditional Chinese Medicine. With over a decade of expertise, Dr. Hao has published extensively in renowned journals, addressing critical topics in cancer research, endothelial cell function, and vascular health.
Publication Profile:
Orcid
Strengths for the Award:
-
Extensive Educational and Research Background: Dr. Huifeng Hao has a comprehensive and solid academic foundation. With a Bachelor’s degree in Clinical Medicine from Hebei Medical University and a Ph.D. in the Integration of Chinese and Western Medicine from Peking University Health Science Center, his educational background is robust. Moreover, his postdoctoral research in Vascular Pharmacology at Peking Union Medical College significantly bolsters his expertise, particularly in vascular biology and its implications in cancer progression.
-
Groundbreaking Research Areas: Dr. Hao’s research primarily focuses on the complex interactions between cancer cells and vascular endothelial cells, along with exploring how Traditional Chinese Medicine (TCM) can influence cancer progression. This intersection of modern pharmacology and traditional medicine offers a unique and innovative approach to cancer therapy. His studies on cancer metastasis, endothelial cell signaling, and the use of TCM as a potential therapeutic strategy for cancer represent cutting-edge work.
-
Impressive Publication Record: Dr. Hao has co-authored numerous high-impact publications in leading journals, such as Phytomedicine, Frontiers in Pharmacology, Journal of Ethnopharmacology, and Journal of Cellular and Molecular Medicine. His work spans across critical cancer pathways, pharmacological interventions, and the exploration of novel therapeutic agents like Marsdenia Tenacissima and Berberine in combating metastasis and endothelial dysfunction.
- His 2022 papers on the modified Bu-Fei decoction’s effects on lung metastasis and the role of CUEDC2 in promoting breast cancer progression are particularly notable for their novel findings and potential clinical applications.
-
Collaborative and Multi-Disciplinary Research: Dr. Hao’s ability to collaborate with a wide array of experts and researchers in diverse fields demonstrates his interdisciplinary approach to solving complex scientific questions. This collaboration enhances the relevance and applicability of his work in various research areas, particularly in cancer biology, pharmacology, and integrative medicine.
-
Pioneering Work on TCM in Cancer Therapy: Dr. Hao’s research on the role of Traditional Chinese Medicine (TCM) in cancer therapy is especially noteworthy. His studies examining how TCM influences tumor microenvironments and endothelial cell interactions provide critical insights into how integrative medicine might be leveraged to treat cancer in combination with conventional therapies. This pioneering research has the potential to redefine cancer treatments and offer patients holistic therapeutic options.
-
Strong Impact on Cancer Research: His work on vascular pharmacology, tumor angiogenesis, and metastasis in lung cancer, particularly through the modulation of transforming growth factor beta receptors and nitric oxide signaling, has significant implications for the development of new cancer therapies. His publications are contributing valuable knowledge toward better understanding cancer progression and discovering more effective treatments.
Areas for Improvement:
-
Broader Research Scope in Clinical Settings: While Dr. Hao’s research has focused heavily on preclinical studies, including animal models and cellular assays, expanding his research into clinical trials or human-based studies would provide essential validation for his findings. Involving clinical datasets and patient-centered research could strengthen the real-world applicability of his work.
-
Increase in Independent Research Funding: While Dr. Hao has contributed significantly to various collaborative projects, securing independent research grants would allow him more freedom to explore his unique research hypotheses in greater depth and broaden the scope of his investigations.
-
Expansion of International Collaborations: While Dr. Hao’s collaborations are impressive, further expanding his international network could provide additional insights and allow him to take his research to the global forefront. Partnerships with leading international cancer research institutions could also amplify the impact of his work.
Education:
- 2004.09-2009.06: Hebei Medical University (Bachelor Degree in Clinical Medicine)
- 2009.09-2014.06: Peking University Health Science Center (Ph.D. in Integration of Chinese and Western Medicine)
- 2014.09-2018.08: Peking Union Medical College (Postdoctoral Training in Vascular Pharmacology)
Dr. Hao’s academic journey spans over a decade of rigorous training, blending Western scientific research with Traditional Chinese Medicine. He received his bachelor’s degree in clinical medicine and later pursued his Ph.D. in an interdisciplinary program that focused on integrating these two approaches to medicine. His postdoctoral research in vascular pharmacology furthered his expertise in understanding the physiological and molecular mechanisms of cancer-related vascular changes.
Experience:
- 2014.09-2018.08: Postdoctoral Researcher, Peking Union Medical College, Vascular Pharmacology
- 2018.08-Present: Assistant Investigator, Peking University Cancer Hospital, Integration of Chinese and Western Medicine
Dr. Hao’s research career spans significant academic institutions in China. During his postdoctoral research at PUMC, he specialized in vascular pharmacology, focusing on the molecular pathways involved in tumor vasculature. At Peking University Cancer Hospital, Dr. Hao continues to investigate how traditional medicine can alter the interactions between cancer cells and endothelial cells, with a goal of developing novel therapeutic strategies for cancer treatment. His interdisciplinary approach has led to multiple breakthrough discoveries in cancer biology and integrative medicine.
Research Focus:
Dr. Hao’s primary research areas include:
- Investigating the interactions between cancer cells and vascular endothelial cells, and how these affect cancer progression
- Exploring the role of Traditional Chinese Medicine (TCM) in regulating cancer cell interactions within the tumor microenvironment, especially with endothelial cells
By bridging the gap between modern biomedical science and traditional medicine, Dr. Hao aims to develop therapies that utilize both modalities to inhibit tumor growth and metastasis. His work focuses on understanding how TCM can modulate endothelial cells and vascular pathways, potentially leading to new treatments for cancer that are more holistic and effective.
Publications Top Notes:
- Modified Bu-Fei decoction inhibits lung metastasis via suppressing angiopoietin-like 4 🫁🦠
- CUEDC2 Drives β-Catenin Nuclear Translocation and Promotes Triple-Negative Breast Cancer Tumorigenesis 🧬💥
- Berberine Suppresses Lung Metastasis of Cancer via Inhibiting Endothelial Transforming Growth Factor Beta Receptor 1 🌱🏥
- Marsdenia tenacissima extract disturbs the interaction between tumor-associated macrophages and non-small cell lung cancer cells by targeting HDGF 🌿🧫
- The cyclic adenosine monophosphate elevating medicine, forskolin, reduces neointimal formation and atherogenesis in mice 🐭💉
- Nitric oxide, a communicator between tumor cells and endothelial cells, mediates the anti-tumor effects of Marsdenia Tenacissima Extract (MTE) 💡🔬
- Marsdenia tenacissima extract promotes gefitinib accumulation in tumor tissues of lung cancer xenograft mice via inhibiting ABCG2 activity 💊🔬
- Marsdenia tenacissima extract dilated small mesenteric arteries via stimulating endothelial nitric oxide synthase and inhibiting calcium influx 🧪🩸
- Protective Role of mPGES-1 (Microsomal Prostaglandin E Synthase-1)-Derived PGE(2) (Prostaglandin E-2) and the Endothelial EP4 (Prostaglandin E Receptor) in Vascular Responses to Injury 💥🩺
- Loss of Endothelial CXCR7 Impairs Vascular Homeostasis, and Cardiac Remodeling After Myocardial Infarction ❤️🫀
Conclusion:
Dr. Huifeng Hao’s contributions to cancer research, particularly the intersection of TCM and Western medicine, make him an excellent candidate for the Best Researcher Award. His innovative studies, combined with his dedication to advancing cancer treatment, position him as a leading researcher in his field. His continued research promises to significantly impact both scientific understanding and clinical practices in cancer therapy.